Last reviewed · How we verify
Rocuronium + sugammadex
Rocuronium + sugammadex is a Neuromuscular blocking agent (rocuronium) + selective relaxant binding agent (sugammadex) Small molecule drug developed by Brno University Hospital. It is currently FDA-approved for Reversal of neuromuscular blockade induced by rocuronium during general anesthesia, Rapid restoration of neuromuscular function in the operating room and recovery room.
Rocuronium is a neuromuscular blocking agent that is rapidly reversed by sugammadex, a selective relaxant binding agent that encapsulates rocuronium molecules to restore neuromuscular function.
Rocuronium is a small molecule antagonist that targets the muscle-type nicotinic acetylcholine receptor. It is used to induce neuromuscular blockade, and sugammadex is used to reverse its effects.
At a glance
| Generic name | Rocuronium + sugammadex |
|---|---|
| Sponsor | Brno University Hospital |
| Drug class | Neuromuscular blocking agent (rocuronium) + selective relaxant binding agent (sugammadex) |
| Target | Nicotinic acetylcholine receptor at the neuromuscular junction (rocuronium); rocuronium molecule itself (sugammadex) |
| Modality | Small molecule |
| Therapeutic area | Anesthesia / Perioperative Medicine |
| Phase | FDA-approved |
Mechanism of action
Rocuronium competitively blocks acetylcholine at the neuromuscular junction, causing paralysis during anesthesia. Sugammadex is a modified gamma-cyclodextrin that forms a tight 1:1 complex with rocuronium in the plasma and at the neuromuscular junction, rapidly removing free rocuronium and allowing spontaneous recovery of neuromuscular function without waiting for hepatic or renal elimination.
Approved indications
- Reversal of neuromuscular blockade induced by rocuronium during general anesthesia
- Rapid restoration of neuromuscular function in the operating room and recovery room
Common side effects
- Bradycardia
- Hypotension
- Nausea and vomiting
- Recurarization (return of neuromuscular blockade)
- Allergic reactions
Key clinical trials
- Impact of Sugammadex Versus Neostigmine on Early Postoperative Pulmonary Function (NA)
- A Dose-response Study to Determine the Right Dosage of Sugammadex as a Reversal Agent of Rocuronium in Infants Between 1 and 24 Months Old (PHASE4)
- Risk of Acute Complications With Rocuronium vs Cisatracurium in Patients With Chronic Kidney Disease (PHASE4)
- Comparison of the Performances of the cTOFR and the mTOFR During Reversal of Deep Neuromuscular Blockade With Sugammadex
- Cardiac Output and Recovery Time (NA)
- Assessment of Endotracheal Tube Temperature Effects in Children Undergoing Adenotonsillectomy (NA)
- Methylprednisolone vs Dexamethasone Interaction With Sugammadex in Pediatric Patients (NA)
- Comparison of Acceleromyography and Electromyography in Obese Patients Undergoing General Anesthesia
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rocuronium + sugammadex CI brief — competitive landscape report
- Rocuronium + sugammadex updates RSS · CI watch RSS
- Brno University Hospital portfolio CI
Frequently asked questions about Rocuronium + sugammadex
What is Rocuronium + sugammadex?
How does Rocuronium + sugammadex work?
What is Rocuronium + sugammadex used for?
Who makes Rocuronium + sugammadex?
What drug class is Rocuronium + sugammadex in?
What development phase is Rocuronium + sugammadex in?
What are the side effects of Rocuronium + sugammadex?
What does Rocuronium + sugammadex target?
Related
- Drug class: All Neuromuscular blocking agent (rocuronium) + selective relaxant binding agent (sugammadex) drugs
- Target: All drugs targeting Nicotinic acetylcholine receptor at the neuromuscular junction (rocuronium); rocuronium molecule itself (sugammadex)
- Manufacturer: Brno University Hospital — full pipeline
- Therapeutic area: All drugs in Anesthesia / Perioperative Medicine
- Indication: Drugs for Reversal of neuromuscular blockade induced by rocuronium during general anesthesia
- Indication: Drugs for Rapid restoration of neuromuscular function in the operating room and recovery room
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing